UK Clinical Trials Sector
In early 2026, the United Kingdom is witnessing a dramatic reduction in the time required to move from trial application to the first patient dosed, thanks to the full implementation of the O’Shaughnessy Review recommendations. These 2026 reforms have streamlined the Health Research Authority (HRA) and MHRA approval processes, creating a "one-stop-shop" for regulatory clearance that is attracting record levels of international pharmaceutical investment.
8 Views